Sign in
Taking people in United StatesPhase 2

Tests empagliflozin for kidney disease in people with sickle cell anemia

Tests empagliflozin to see if it slows kidney decline in adults with sickle cell anemia.

Key facts

Who runs it
University of Illinois Chicago
Where
Chicago, United StatesSee the site
Trial code
Registry title
Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin
Status
Recruiting
Phase
Phase 2
People taking part
20 people, planned
Started
8 Apr 2026
Expected to end
Oct 2030
Type of study
Interventional
Treatments tested
  • Empagliflozin (oral)
Record updated
19 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with sickle cell anemia (HbSS or HbSβ0-thalassemia) who have protein in the urine (albuminuria). It tests whether empagliflozin can slow kidney damage.

Age
18 to 60 years
Sex
All sexes can join.
Disease stage
Sickle cell anemia (HbSS or HbSβ0-thalassemia) with albuminuria: UACR of 100 - 2,000 mg/g creatinine at screening. Hemoglobin of at least 5.5 g/dL at screening.
Earlier treatment
If taking Endari: stable dose for at least one month. If on crizanlizumab or regular red blood cell transfusions: started at least 3 months before consent. If taking an ACE inhibitor or ARB: stable dose for at least 3 months. Cannot have had a reaction to an SGLT2 inhibitor before.
Biomarker or test result
Documented sickle cell genotype (HbSS or HbSβ0-thalassemia). UACR of 100 - 2,000 mg/g creatinine.

Main reasons for not taking part

  • Diabetes mellitus
  • Pregnant or breast feeding, or unwilling to use birth control
  • Moderate to severe chronic kidney disease (eGFR < 30 mL/min/1.73m2), dialysis, or a kidney transplant
  • Known active hepatitis A, B or C, or known HIV positive
  • Hospitalized for a sickle cell crisis within 14 days before consent

The registry criteria, word for word

Show all 25 criteriaShow less

Who can take part

  • Documentation of SCA genotype (HbSS or HbSβ0-thalassemia)
  • Albuminuria defined by a UACR of 100 - 2,000 mg/g creatinine at the screening
  • Hemoglobin (Hb) ≥ 5.5 g/dL during screening
  • For participants taking Endari, the dose of Endari must be stable for at least one month prior to signing the ICF and with no anticipated need for dose adjustments during the study
  • For participants on crizanlizumab or chronic red blood cell transfusions, the therapy must have started at least 3 months prior to consent
  • For participants taking an angiotensin converting enzyme inhibitor (ACEi) or angiotensin II receptor blocker (ARB), the dose must be stable for at least 3 months prior to signing the ICF and with no anticipated need for dose adjustments during the study, in the opinion of the Investigator
  • Participants must demonstrate regular compliance with clinic visits and outpatient management
  • Participants, if female and of childbearing potential, will use highly effective methods of contraception from study start to 30 days after the last dose of the study drug
  • Participant has provided documented informed consent or assent

Who cannot take part

  • Concurrent diagnosis of diabetes mellitus
  • Hospitalized for sickle cell crisis or other vaso-occlusive event within 14 days prior to signing consent
  • History of unstable or deteriorating cardiac or pulmonary disease within 6 months prior to consent including but not limited to the following:; Unstable angina pectoris or myocardial infarction or elective coronary intervention; Uncontrolled clinically significant arrhythmias
  • Any condition affecting drug absorption, such as major surgery involving the stomach (e.g. bariatric surgery) or small intestine (prior cholecystectomy is acceptable)
  • Participated in another clinical trial of an investigational agent (or medical device) within 30 days or 5 half-lives of agent, whichever is longer, or is currently participating in another trial of an investigational agent or medical device)
  • Contraindication to MRI (certain pacemakers, electronic implants, shrapnel in the eyes, or certain intracranial aneurysm clips)
  • Active or open leg ankle ulcer
  • Chronic urinary tract infection
  • Participants with acute bacterial infection requiring antibiotic use should delay screening/enrollment until the course of antibiotic therapy has been completed
  • Participants with known active hepatitis A, B, or C or who are known to be human immunodeficiency virus (HIV) positive
  • History of malignancy within the past 2 years prior to treatment Day 1 requiring chemotherapy and/or radiation (with the exception of local therapy for non-melanoma skin malignancy)
  • Medical, psychological, or behavioral conditions, which, in the opinion of the Investigator, may preclude safe participation, confound study interpretation, interfere with compliance, or preclude informed consent
  • Prior hypersensitivity or intolerance to a sodium-glucose cotransporter-2 inhibitor (SGLT2i)
  • Hepatic dysfunction characterized by alanine aminotransferase (ALT) >5× ULN
  • Moderate to severe CKD (defined by an eGFR < 30 mL/min/1.73m2, on chronic dialysis, or having received a kidney transplantation)
  • Female who is breast feeding, pregnant, or unwilling to use birth control as described in the protocol

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 60 years old?

Where in United States

  • University of Illinois Chicago, Sickle Cell CenterChicago, United StatesContact: Santosh L Saraf, MDTaking people

About the trial

What the trial wants to find out

Sickle cell anemia (SCA) is an inherited red blood disorder. The kidneys are among the most commonly affected organ systems in SCA. The Food and Drug Administration (FDA) has approved empagliflozin as a treatment to reduce the decline of kidney function in those with kidney disease. The proposed research study aims to determine whether empagliflozin can prevent the progression of kidney dysfunction in patients with sickle cell anemia (SCA) who are at high risk of developing advanced chronic kidney disease (CKD).

The group in the trial

  • TreatmentTreatment being tested

    Empagliflozin

    Treatment: Empagliflozin (oral)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin
Plain-language title
Tests empagliflozin for kidney disease in people with sickle cell anemiaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07175051, who can take part
Record updated
19 May 2026